Investigational Drug Information for ETX2514
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for ETX2514?
ETX2514 is an investigational drug.
There have been 7 clinical trials for ETX2514.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 5th 2019.
The most common disease conditions in clinical trials are Infections, Renal Insufficiency, and Bacteremia. The leading clinical trial sponsors are Entasis Therapeutics, Clinartis, and [disabled in preview].
There are two US patents protecting this investigational drug and forty-two international patents.
Summary for ETX2514
| US Patents | 2 |
| International Patents | 42 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2019-09-05) |
| Vendors | 6 |
Recent Clinical Trials for ETX2514
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex | Entasis Therapeutics | Phase 3 |
| Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects | Entasis Therapeutics | Phase 1 |
| Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers | Entasis Therapeutics | Phase 1 |
Clinical Trial Summary for ETX2514
Top disease conditions for ETX2514
Top clinical trial sponsors for ETX2514
US Patents for ETX2514
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ETX2514 | See Plans and Pricing | Beta-lactamase inhibitor compounds | Entasis Therapeutics Limited (London, GB) | See Plans and Pricing |
| ETX2514 | See Plans and Pricing | .beta.-lactamase inhibitor compounds | Entasis Therapeutics Limited (London, GB) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ETX2514
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ETX2514 | Argentina | AR090539 | 2032-04-02 | See Plans and Pricing |
| ETX2514 | Australia | AU2013245399 | 2032-04-02 | See Plans and Pricing |
| ETX2514 | Canada | CA2866467 | 2032-04-02 | See Plans and Pricing |
| ETX2514 | Chile | CL2014002589 | 2032-04-02 | See Plans and Pricing |
| ETX2514 | China | CN104364254 | 2032-04-02 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
